The causes and consequences of genetic heterogeneity in cancer evolution, Nature, vol.501, issue.7467, pp.338-383, 2013. ,
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A J Clin, vol.00, issue.00, pp.1-31, 2018. ,
Global Cancer Statistics: 2011, CA Cancer J Clin, vol.61, issue.2, pp.69-90, 2011. ,
Mechanism of activation of a human oncogene, Nature, vol.300, issue.5888, pp.143-152, 1982. ,
Mutation and cancer: statistical study of retinoblastoma, Proc Natl Acad Sci U S A, vol.68, issue.4, pp.820-823, 1971. ,
The hallmarks of cancer, Cell, vol.100, issue.1, pp.57-70, 2000. ,
Inhibition of ras-induced proliferation and cellular transformation by p16, Science, vol.267, pp.249-52, 1995. ,
Induction of apoptosis in fibroblasts by c-myc protein, Cell, vol.69, issue.1, pp.119-147, 1992. ,
Further exploration of stages in carcinogenesis, Carcinog Compr Surv, vol.7, pp.41-43, 1982. ,
How many mutations are required for tumorigenesis? Implications from human cancer data, Mol Carcinog, vol.7, issue.3, pp.139-185, 1993. ,
Tumour heterogeneity and resistance to cancer therapies, Nat Rev Clin Oncol, vol.15, issue.2, pp.81-94, 2017. ,
Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-74, 2011. ,
The serial cultivation of human diploid cell strains, Exp Cell Res, vol.25, issue.3, pp.585-621, 1961. ,
Emerging biological principles of metastasis, Cell, vol.168, issue.4, pp.670-91, 2016. ,
On respiratory impairment in cancer cells, Science, vol.124, issue.3215, pp.269-70, 1956. ,
Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion, Science, vol.331, issue.6024, pp.1565-70, 2011. ,
TGF-b and immune cells: an important regulatory axis in the tumor microenvironment and progression, Trends Immunol, vol.31, issue.6, pp.220-227, 2010. ,
Myeloidderived suppressor cells: linking inflammation and cancer, J Immunol, vol.182, issue.8, pp.4499-506, 2009. ,
Immunity, Inflammation, and cancer, Cell, vol.140, issue.6, pp.883-99, 2010. ,
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, vol.351, issue.6280, pp.1463-1472, 2016. ,
Necrotic death as a cell fate, Genes Dev, vol.20, issue.1, pp.1-15, 2006. ,
Intracellular signaling mechanisms in photodynamic therapy, Biochim Biophys Acta -Rev Cancer, vol.1704, issue.2, pp.59-86, 2004. ,
, Tumour growth. Immunology, vol.4, pp.1-8, 2004.
Universal patterns of selection in cancer and somatic tissues, Cell, vol.171, issue.5, 2017. ,
Autonomic nerve development cancer progression, Science, vol.341, issue.6142, pp.1-10, 2013. ,
Progenitors from the central nervous system drive neurogenesis in cancer, Nature, vol.569, issue.7758, pp.672-680, 2019. ,
URL : https://hal.archives-ouvertes.fr/cea-02186559
The DNA damage response and cancer therapy, Nature, vol.481, issue.7381, pp.287-94, 2012. ,
Mutational signatures associated with tobacco smoking in human cancer, Science, vol.354, issue.6312, pp.618-640, 2016. ,
Clock-like mutational processes in human somatic cells, Nat Genet, vol.47, issue.12, pp.1402-1409, 2015. ,
The topography of mutational processes in breast cancer genomes, Nat Commun, vol.7, p.11383, 2016. ,
Landscape of somatic mutations in 560 breast cancer whole-genome sequences, Nature, vol.534, issue.7605, pp.47-54, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01388447
The repertoire of mutational signatures in human cancer, Nature, vol.578, issue.7793, pp.94-101, 2020. ,
Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, vol.499, issue.7457, pp.214-222, 2013. ,
Net -ICGC/TCGA pan-cancer analysis of whole genomes. Pan-cancer analysis of whole genomes, Nature, vol.578, issue.7793, pp.82-93, 2020. ,
Cancer genome landscapes, Science, vol.339, issue.6127, pp.1546-58, 2013. ,
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers, Nat Rev Cancer, vol.18, issue.11, pp.696-705, 2018. ,
paramètre limitant l'efficacité des thérapies ciblées en oncologie tome xx > n8x > xx 2020 ,
L'instabilité génomique, paramètre limitant l'efficacité des thérapies ciblées en oncologie, Bull Cancer, 2020. ,
Oncogenic signaling pathways in the cancer Genome Atlas, Cell, vol.173, issue.2, 2018. ,
Pathway and network analysis of more than 2500 whole cancer genomes, Nat Commun, vol.11, issue.1, pp.1-17, 2020. ,
Integrative clinical genomics of metastatic cancer, Nature, vol.548, pp.297-303, 2017. ,
Comprehensive analysis of hypermutation in human cancer, Cell, vol.171, pp.1042-56, 2017. ,
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med, vol.23, issue.6, pp.703-716, 2017. ,
The multifaceted role of chromosomal instability in cancer and its microenvironment, Cell, vol.174, issue.6, pp.1-27, 2018. ,
Epigenetic plasticity and the hallmarks of cancer, vol.357, p.80, 2017. ,
The clonal evolution of tumor cell populations, Science, vol.194, issue.4260, pp.23-31, 1976. ,
Accumulation of driver and passenger mutations during tumor progression, Proc Natl Acad Sci, vol.107, issue.43, pp.18545-50, 2010. ,
Clonal evolution in cancer, Nature, vol.481, issue.7381, pp.306-319, 2012. ,
Parallel progression of tumour and metastases, Nat Rev Cancer, vol.10, issue.2, p.156, 2009. ,
The evolutionary history of 2658 cancers, Nature, vol.578, issue.7793, pp.122-130, 2020. ,
Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases, Nat Genet, vol.52, issue.7, pp.701-709, 2020. ,
Classifying the evolutionary and ecological features of neoplasms, Nat Rev Cancer, vol.17, issue.10, pp.605-624, 2017. ,
Cells of origin in cancer, Nature, vol.469, pp.314-336, 2011. ,
Tracking the evolution of non-small-cell lung cancer, N Engl J Med, vol.376, issue.22, pp.2109-2130, 2017. ,
Quantitative evidence for early metastatic seeding in colorectal cancer, Nat Genet, vol.51, pp.1113-1135, 2019. ,
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing, Nature, vol.481, issue.7382, pp.506-516, 2012. ,
Toxicity of primaquine in caucasians, JAMA J Am Med Assoc, vol.149, issue.17, p.1563, 1952. ,
Drug reactions, enzymes, and biochemical genetics, J Am Med Assoc, vol.165, issue.7, p.835, 1957. ,
Pharmacogenetics -five decades of therapeutic lessons from genetic diversity, Nat Rev Genet, vol.5, issue.9, pp.669-76, 2004. ,
Integrating genetic approaches into the discovery of anticancer drugs, Science (80-), vol.278, issue.5340, pp.1064-1072, 1997. ,
The cancer biomarker problem, Nature, vol.452, issue.7187, pp.548-52, 2008. ,
Enabling personalized cancer medicine through analysis of gene-expression patterns, Nature, vol.452, issue.7187, pp.564-70, 2008. ,
Targeted cancer therapy, Nature, vol.432, issue.7015, pp.294-301, 2004. ,
Molecularly targeted cancer therapy: some lessons from the past decade, Trends Pharmacol Sci, vol.35, issue.1, pp.41-50, 2014. ,
Ullrichlt A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor, Mol Cell Biol, vol.9, issue.3, pp.1165-72, 1989. ,
Imatinib and beyond -Exploring the full potential of targeted therapy for CML, Nat Rev Clin Oncol, vol.6, issue.9, pp.535-578, 2009. ,
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia, N Engl J Med, vol.348, issue.11, pp.994-1004, 2003. ,
Addiction to oncogenes -the Achilles Heal of Cancer. Science (80-), vol.297, pp.64-69, 2002. ,
Oncogene addiction, Cancer Res, vol.68, issue.9, pp.3077-81, 2008. ,
Oncogenic shock'': Explaining oncogene addiction through differential signal attenuation, Clinical Cancer Research, pp.4392-4397, 2006. ,
Principles of cancer therapy: oncogene and non-oncogene addiction, Cell, vol.136, issue.5, pp.823-860, 2009. ,
The concept of synthetic lethality in the context of anticancer therapy, Nat Rev Cancer, vol.5, issue.9, pp.689-98, 2005. ,
Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura, Genetics, vol.31, issue.3, pp.269-90, 1946. ,
Synthetic lethality and cancer, Nat Rev Genet, vol.18, issue.10, pp.613-636, 2017. ,
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, issue.7035, pp.917-938, 2005. ,
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, vol.434, issue.7035, pp.913-920, 2005. ,
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors, Annu Rev Med, vol.66, issue.1, pp.455-70, 2015. ,
Genetic interactions in cancer progression and treatment, Cell, vol.145, issue.1, pp.30-38, 2011. ,
A global genetic interaction network maps a wiring diagram of cellular function, Science, vol.353, issue.6306, pp.1381-887, 2016. ,
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, vol.462, issue.7269, pp.108-120, 2009. ,
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes, Nat Genet, vol.49, issue.6, pp.856-64, 2017. ,
Somatic mRNA analysis of BRCA1 splice variants provides a direct theranostic impact on PARP inhibitors, Mol diagnosis Ther, vol.24, pp.233-276, 2020. ,
URL : https://hal.archives-ouvertes.fr/inserm-02512969
Role of non-coding sequence variants in cancer, Nat Rev Genet, vol.17, issue.2, pp.93-108, 2016. ,
Noncoding RNA networks in cancer, Nat Rev Cancer, vol.18, issue.1, pp.5-18, 2017. ,